Epidemiology and risk factors of lithiasic complications following treatment with indinavir;Épidémiologie et facteurs de risque des complications lithiasiques de l'indinavir

Feuillets de Biologie

Volumn 42, Issue 242, 2001, Pages 31-34

  Daudon, M ^a   Estepa, L ^a   Viard, J P ^a   Jungers, P ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0034791443     PISSN: 04282779     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. HIV-1 protease inhibitors. A review for clinicians
2. Indinavir nephropathy
3. Crystalluria and urinary tract abnormalities associated with indinavir
4. Indinavir crystal deposits associated with tubulointerstitial nephropathy
5. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed
6. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
7. Urolithiasis and the protease inhibitor indinavir
8. Urinary stones in HIV-1-positive patients treated with indinavir
9. Detection of indinavir crystals in urine: Dependence on method of analysis
10. A prospective study of urinalysis abnormalities in HIV+ individuals treated with indinavir
11. Indinavir crystalluria. Identification of patients at increased risk of developing nephrotoxicity
12. High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma
13. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine
14. Single-dose pharmacokinetics of indinavir and the effect of food